
Longeveron Inc (NASDAQ:LGVN) announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal.
The 33-subject trial met its primary endpoint, demonstrating that Lomecel-B was well tolerated.